Gideon Bollag

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

Scott M. Wilhelm, Christopher Carter, LiYa Tang et al. · Cancer Research · 2004 · 4K citations · Full text

Medicine, Oncology, Pharmacology +17

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Gideon Bollag, Peter Hirth, James Tsai et al. · Nature · 2010 · 1.8K citations

Medicine, Oncology, Pharmacology +14

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

Poulikos I. Poulikakos, Chao Zhang, Gideon Bollag et al. · Nature · 2010 · 1.8K citations · Full text

Life Sciences, Cancer Biology, Molecular Biology +15

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

James Tsai, John Tayu Lee, Weiru Wang et al. · Proceedings of the National Academy of Sciences · 2008 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +15

<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

Fei Su, Amaya Virós, Carla Milagre et al. · New England Journal of Medicine · 2012 · 1K citations · Full text

Medicine, Dermatology, Oncology +13